Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, has shown promising efficacy in modulating biomarkers associated with non-alcoholic steatohepatitis (NASH) among individuals with type 2 diabetes. The gene discussed is GIP; the disease is metabolic dysfunction-associated steatohepatitis.